Red de medicina de precisión en enfermedades complejas (RMPEC) - GIC 21/095
Gustave Roussy Cancer Campus
Villejuif, FranciaPublicaciones en colaboración con investigadoras/es de Gustave Roussy Cancer Campus (4)
2024
-
ATM germ line pathogenic variants affect outcomes in children with ataxia-telangiectasia and hematological malignancies
Blood, Vol. 144, Núm. 11, pp. 1193-1205
2023
-
Molecular characterisation defines clinically-actionable heterogeneity within Group 4 medulloblastoma and improves disease risk-stratification
Acta Neuropathologica, Vol. 145, Núm. 5, pp. 651-666
2021
-
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial
The Lancet Oncology, Vol. 22, Núm. 4, pp. 463-475
2017
-
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet Oncology, Vol. 18, Núm. 12, pp. 1688-1700